论文部分内容阅读
目的观察乳腺癌术前应用多西他赛联合排毒汤新辅助化疗的疗效。方法选取120例经穿刺细胞学确诊的乳腺癌患者,根据治疗方案的不同分为两组,观察组患者给予多西他赛+表阿霉素(TA)方案化疗联合排毒汤,对照组患者给予环磷酰胺+表阿霉素(AC)方案化疗联合排毒汤。两组患者均治疗4个疗程,并接受手术治疗。观察两组患者临床疗效及并发症发生情况。结果观察组患者总有效率为91.7%,对照组患者为78.3%,差异有统计学意义(P<0.05)。结论多西他赛联合排毒汤新辅助化疗应用于乳腺癌术前治疗,疗效显著,并发症少,值得临床推广。
Objective To observe the effect of docetaxel combined detoxification decoction with neoadjuvant chemotherapy before breast cancer. Methods 120 cases of breast cancer confirmed by biopsy were divided into two groups according to different treatment regimens. The patients in the observation group were treated with docetaxel + epirubicin (TA) regimen combined with detoxification decoction and the control group with Cyclophosphamide + epirubicin (AC) regimen chemotherapy combined detox soup. Two groups of patients were treated 4 courses, and received surgery. The clinical efficacy and complications of the two groups were observed. Results The total effective rate was 91.7% in the observation group and 78.3% in the control group, the difference was statistically significant (P <0.05). Conclusion Docetaxel combined detoxification soup neoadjuvant chemotherapy for preoperative breast cancer treatment, significant effect, fewer complications, it is worth clinical promotion.